Abstract
The recognition that malfunction of the microtubule (MT) associated protein tau is likely to play a defining role in the onset and/or progression of a number of neurodegenerative diseases, including Alzheimers disease, has resulted in the initiation of drug discovery programs that target this protein. Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons. The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents. Under pathological conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss. This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small molecule inhibitors of tau aggregation.
Keywords: Protein-protein interaction, tau, Alzheimer's disease, neurodegenerative tauopathies, microtubule-stabilizing agents, aggregation inhibitors, microtubule, neuronal loss, cyclosporine A, FK506, taxanes, vinca alkaloids, RGD-mimetics, central nervous system, Pick's disease, frontotemporal dementia, neurofibrillary tangles, frontotemporal lobar degeneration, tau-MT complex, phosphorylation, antineoplastic agents, rheumatoid arthritis, psoriasis, paclitaxel, blood-brain barrier, P-glycoprotein, ATP-binding cassette, IDN5109, brain to plasma ratio, TXD258, Larotaxel, ANG1005, Angiopep-2, Epothilones, Ixabepilone, desoxyepothilones, discodermolide, dictyostatin, cyclostreptin, davunetide, N-methyl-D-aspartate, phenothiazines, anthraquinones, N-phenylamines, thiazolyl-hydrazides, rhodanines, quinoxalines, aminothienopyridazines
Current Topics in Medicinal Chemistry
Title: Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies
Volume: 11 Issue: 3
Author(s): C. Ballatore, K. R. Brunden, J. Q. Trojanowski, V. M.-Y. Lee, A. B. Smith and D. M. Huryn
Affiliation:
Keywords: Protein-protein interaction, tau, Alzheimer's disease, neurodegenerative tauopathies, microtubule-stabilizing agents, aggregation inhibitors, microtubule, neuronal loss, cyclosporine A, FK506, taxanes, vinca alkaloids, RGD-mimetics, central nervous system, Pick's disease, frontotemporal dementia, neurofibrillary tangles, frontotemporal lobar degeneration, tau-MT complex, phosphorylation, antineoplastic agents, rheumatoid arthritis, psoriasis, paclitaxel, blood-brain barrier, P-glycoprotein, ATP-binding cassette, IDN5109, brain to plasma ratio, TXD258, Larotaxel, ANG1005, Angiopep-2, Epothilones, Ixabepilone, desoxyepothilones, discodermolide, dictyostatin, cyclostreptin, davunetide, N-methyl-D-aspartate, phenothiazines, anthraquinones, N-phenylamines, thiazolyl-hydrazides, rhodanines, quinoxalines, aminothienopyridazines
Abstract: The recognition that malfunction of the microtubule (MT) associated protein tau is likely to play a defining role in the onset and/or progression of a number of neurodegenerative diseases, including Alzheimers disease, has resulted in the initiation of drug discovery programs that target this protein. Tau is an endogenous MT-stabilizing agent that is highly expressed in the axons of neurons. The MT-stabilizing function of tau is essential for the axonal transport of proteins, neurotransmitters and other cellular constituents. Under pathological conditions, tau misfolding and aggregation results in axonal transport deficits that appear to have deleterious consequences for the affected neurons, leading to synapse dysfunction and, ultimately, neuronal loss. This review focuses on both progress and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function and (B) small molecule inhibitors of tau aggregation.
Export Options
About this article
Cite this article as:
Ballatore C., R. Brunden K., Q. Trojanowski J., M.-Y. Lee V., B. Smith A. and M. Huryn D., Modulation of Protein-Protein Interactions as a Therapeutic Strategy for the Treatment of Neurodegenerative Tauopathies, Current Topics in Medicinal Chemistry 2011; 11 (3) . https://dx.doi.org/10.2174/156802611794072605
DOI https://dx.doi.org/10.2174/156802611794072605 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Palladacycles as Antimicrobial Agents
Current Medicinal Chemistry Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Perspectives of Benzimidazole Derivatives as Anticancer Agents in the New Era
Anti-Cancer Agents in Medicinal Chemistry Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Friend or Foe: UCHL3 Mediated Carcinogenesis and Current Approaches in Small Molecule Inhibitors’ Development
Current Medicinal Chemistry Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis and In Vitro Evaluation of Some Isatin-Thiazolidinone Hybrid Analogues as Anti-Proliferative Agents
Medicinal Chemistry Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Current Cancer Drug Targets Opioid Receptor Interacting Proteins and the Control of Opioid Signaling
Current Pharmaceutical Design Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets